Ranitidina Genfar

Ranitidina Genfar may be available in the countries listed below.

Ingredient matches for Ranitidina Genfar

Ranitidine

Ranitidine is reported as an ingredient of Ranitidina Genfar in the following countries:

• Colombia


• Ecuador

Ranitidine hydrochloride (a derivative of Ranitidine) is reported as an ingredient of Ranitidina Genfar in the following countries:

• Peru

International Drug Name Search

Atacand HCT

Atacand HCT is a brand name of candesartan/hydrochlorothiazide, approved by the FDA in the following formulation(s):

ATACAND HCT (candesartan cilexetil; hydrochlorothiazide - tablet; oral)

• 
  Manufacturer: ASTRAZENECA
  
  Approval date: September 5, 2000
  
  Strength(s): 16MG;12.5MG, 32MG;12.5MG
  


• 
  Manufacturer: ASTRAZENECA
  
  Approval date: May 16, 2008
  
  Strength(s): 32MG;25MG ^[RLD]

Has a generic version of Atacand HCT been approved?

No. There is currently no therapeutically equivalent version of Atacand HCT available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Atacand HCT. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-c arboxylate and compositions and methods of pharmaceutical use thereof
  Patent 5,196,444
  Issued: March 23, 1993
  Inventor(s): Naka; Takehiko & Nishikawa; Kohei & Kato; Takeshi
  Assignee(s): Takeda Chemical Industries, Ltd.
  1-(Cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-car boxylate or a pharmaceutically acceptable salt thereof has potent angiotensin II antihypertensive activity, thus being useful as therapeutic agents for treating circulatory system diseases such as hypertensive diseases, heart diseases (e.g. hypercardia, heart failure, cardiac infarction, etc.), strokes, cerebral apoplexy, nephritis, etc.
  
  Patent expiration dates:
  
  
  • June 4, 2012
    
    ✓ 
    Patent use: TREATMENT OF HYPERTENSION
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • December 4, 2012
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Pharmaceutical compositions for oral use and method of preparing them
  Patent 5,534,534
  Issued: July 9, 1996
  Inventor(s): Makino; Tadashi & Mizukami; Yashio & Kikuta; Jun-ichi
  Assignee(s): Takeda Chemical Industries, Ltd.
  A pharmaceutical composition for oral use comprising an effective amount of a compound of the formula (I) having antagonistic action to angiotensin II ##STR1## (wherein the ring W is an optionally substituted N-containing heterocyclic residue; R.sup.3 is a group capable of forming an anion or a group convertible thereinto; X is a direct bond or a spacer having an atomic length of two or less between the phenylene group and the phenyl group; and n is an integer of 1 or 2) and an oily substance having a lower melting point, and a method for preparing a pharmaceutical composition for oral use comprising an effective amount of a compound of the formula (I) and an oily substance having a lower melting point, which comprises admixing the compound of the formula (I) with an oily substance having a lower melting point and then subjecting the mixture to molding.
  
  Patent expiration dates:
  
  
  • July 9, 2013
    
    ✓ 
    Drug product
  
  
  
  • January 9, 2014
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Benzimidazole derivatives and use thereof
  Patent 5,705,517
  Issued: January 6, 1998
  Inventor(s): Naka; Takehiko & Nishikawa; Kohei
  Assignee(s): Takeda Chemical Industries, Ltd.
  Benzimidazole derivatives of the formula (I): ##STR1## wherein the ring A is a benzene ring which may optionally contain substitution in addition to the R' group; R' is hydrogen or an optionally substituted hydrocarbon residue; R.sup.2 is a group capable of forming an anion or a group convertible thereinto; X is a direct bond or a spacer having an atomic length of two or less between the phenylene group and the phenyl group; R' is carboxyl, an ester thereof, an amide thereof or a group capable of forming an anion or convertible to an anion; Y is --O--, --S(O).sub.m -- or --N(R.sup.4)-- wherein m is an integer of 0, 1 or 2 and R.sup.4 is hydrogen or an optionally substituted alkyl group; and n is an integer of 1 or 2; and the pharmaceutically acceptable salts thereof, have potent angiotensin II antagonistic activity and antihypertensive activity, thus being useful as therapeutic agents for treating circulatory system diseases such as hypertensive diseases, heart diseases (e.g. hypercardia, heart failure, cardiac infarction, etc.), strokes, cerebral apoplexy, nephritis, etc.
  
  Patent expiration dates:
  
  
  • October 18, 2011
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Pharmaceutical composition for angiotensin II-mediated diseases
  Patent 5,721,263
  Issued: February 24, 1998
  Inventor(s): Inada; Yoshiyuki & Kubo; Keiji
  Assignee(s): Takeda Chemical Industries, Ltd.
  This invention relates to a pharmaceutical composition for angiotensin II-mediated diseases, which comprises a compound having angiotensin II antagonistic activity of the formula ##STR1## wherein R.sup.1 is H or an optionally substituted hydrocarbon residue; R.sup.2 is an optionally esterified carboxyl group; R.sup.3 is a group capable of forming an anion or a group convertible thereinto; X is a covalent bond between the 2 phenyl rings or a spacer having a chain length of 1 to 2 atoms as the linear moiety between the adjoining phenylene group and phenyl group; n is 1 or 2; the ring A is a benzene ring having 1 or 2 optional substituents in addition to R.sup.2 ; and Y is a bond, --O--, --S(O)m-- (wherein m is 0, 1 or 2) or --N(R.sup.4)-- (wherein R.sup.4 is H or an optionally substituted alkyl group), or a pharmaceutically acceptable salt thereof in combination with a compound having diuretic activity or a compound having calcium antagonistic activity.
  
  Patent expiration dates:
  
  
  • February 24, 2015
    
    ✓ 
    Patent use: TREATMENT OF HYPERTENSION
    ✓ 
    Drug product
  
  



• 
  Pharmaceutical composition for angiotensin II-mediated diseases
  Patent 5,958,961
  Issued: September 28, 1999
  Inventor(s): Inada; Yoshiyuki & Kubo; Keiji
  Assignee(s): Takeda Chemical Industries, Ltd.
  This invention relates to a pharmaceutical composition for angiotensin II-mediated diseases, which comprises a compound having angiotensin II antagonistic activity of the formula ##STR1## wherein R.sup.1 is H or an optionally substituted hydrocarbon residue; R.sup.2 is an optionally esterified carboxyl group; R.sup.3 is a group capable of forming an anion or a group convertible thereinto; X is a covalent bond between the 2 phenyl rings or a spacer having a chain length of 1 to 2 atoms as the linear moiety between the adjoining phenylene group and phenyl group; n is 1 or 2; the ring A is a benzene ring having 1 or 2 optional substituents in addition to R.sup.2 ; and Y is a bond, --O--, --S(O)m- (wherein m is 0, 1 or 2) or --N(R.sup.4)-- (wherein R.sup.4 is H or an optionally substituted alkyl group), or a pharmaceutically acceptable salt thereof in combination with a compound having diuretic activity or a compound having calcium antagonistic activity.
  
  Patent expiration dates:
  
  
  • June 6, 2014
    
    ✓ 
    Patent use: TREATMENT OF HYPERTENSION
    ✓ 
    Drug product
  
  



• 
  Benzimidazole derivatives, their production and use
  Patent 7,538,133
  Issued: May 26, 2009
  Inventor(s): Naka; Takehiko & Nishikawa; Kohei & Kato; Takeshi
  Assignee(s): Takeda Pharmaceutical Company Limited
  Benzimidazole derivatives of the formula (I): wherein the ring A is a benzene ring which may optionally contain substitution in addition to the R′ group; R1 is hydrogen or an optionally substituted hydrocarbon residue; R2 is a group capable of forming an anion or a group convertible thereinto; X is a direct bond or a spacer having an atomic length of two or less between the phenylene group and the phenyl group; R′ is carboxyl, an ester thereof, an amide thereof or a group capable of forming an anion or convertible to an anion; Y is —O—, —S(O)m— or —N(R4)— wherein m is an integer of 0, 1 or 2 and R4 is hydrogen or an optionally substituted alkyl group; and n is an integer of 1 or 2; and the pharmaceutically acceptable salts thereof, have potent angiotensin II antagonistic activity and antihypertensive activity, thus being useful as therapeutic agents for treating circulatory system diseases such as hypertensive diseases, heart diseases (e.g. hypercardia, heart failure, cardiac infarction, etc.), strokes, cerebral apoplexy, nephritis, etc.
  
  Patent expiration dates:
  
  
  • October 18, 2011
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Atacand HCT Consumer Information (Wolters Kluwer)
• Atacand HCT Consumer Information (Cerner Multum)
• Atacand HCT Advanced Consumer Information (Micromedex)
• Candesartan/Hydrochlorothiazide Consumer Information (Wolters Kluwer)
• Hydrochlorothiazide and candesartan Consumer Information (Cerner Multum)
• Atacand Oral Advanced Consumer Information (Micromedex)
• Candesartan and hydrochlorothiazide Advanced Consumer Information (Micromedex)

Calcio D Isdin

Calcio D Isdin may be available in the countries listed below.

Ingredient matches for Calcio D Isdin

Calcium Carbonate

Calcium Carbonate is reported as an ingredient of Calcio D Isdin in the following countries:

• Spain

Colecalciferol

Colecalciferol is reported as an ingredient of Calcio D Isdin in the following countries:

• Spain

International Drug Name Search

Daunorrubicina

Daunorrubicina may be available in the countries listed below.

Ingredient matches for Daunorrubicina

Daunorubicin

Daunorubicin hydrochloride (a derivative of Daunorubicin) is reported as an ingredient of Daunorrubicina in the following countries:

• Chile

International Drug Name Search

Carvedilol Cinfa

Carvedilol Cinfa may be available in the countries listed below.

Ingredient matches for Carvedilol Cinfa

Carvedilol

Carvedilol is reported as an ingredient of Carvedilol Cinfa in the following countries:

• Spain

International Drug Name Search

Colocarb

Colocarb may be available in the countries listed below.

Ingredient matches for Colocarb

Charcoal

Charcoal, Activated is reported as an ingredient of Colocarb in the following countries:

• France

International Drug Name Search

Retin-A Gel

Pronunciation: TREH-tih-noyn
Generic Name: Tretinoin
Brand Name: Examples include Avita and Retin-A

Retin-A Gel is used for:

Treating acne. It may also be used for other conditions as determined by your doctor.

Retin-A Gel is a vitamin A derivative. How it exerts its beneficial effects against acne is not fully known. Tretinoin appears to increase skin-cell turnover and to reduce the tendency for skin cells to stick together. This reduces the formation of acne and allows quicker healing of acne that does develop.

Do NOT use Retin-A Gel if:

• you are allergic to any ingredient in Retin-A Gel

Contact your doctor or health care provider right away if any of these apply to you.

Before using Retin-A Gel:

Some medical conditions may interact with Retin-A Gel. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you have eczema, an abnormally high white blood cell count, or a sunburn

Some MEDICINES MAY INTERACT with Retin-A Gel. Because little, if any, of Retin-A Gel is absorbed into the blood, the risk of it interacting with another medicine is low.

Ask your health care provider if Retin-A Gel may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Retin-A Gel:

Use Retin-A Gel as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Retin-A Gel is for external use only.


• Apply a thin film of medicine to the affected area. Rub in gently.


• Remove all cosmetics with a mild soap before applying Retin-A Gel. Gently dry the area. Wait 20 to 30 minutes to make sure that your skin is completely dry.


• Wash your hands immediately after using Retin-A Gel.


• If you miss a dose of Retin-A Gel, skip the missed dose and go back to your regular dosing schedule.

Ask your health care provider any questions you may have about how to use Retin-A Gel.

Important safety information:

• Avoid getting Retin-A Gel in your eyes, nose, or mouth. If you get Retin-A Gel in your eyes, rinse thoroughly with water.


• Retin-A Gel may cause you to become sunburned more easily. Avoid the sun, sunlamps, or tanning booths until you know how you react to Retin-A Gel. Use a sunscreen or wear protective clothing if you must be outside for more than a short time.


• For the first 2 to 3 weeks of treatment, your skin condition may appear to worsen. This is expected. Do not stop using Retin-A Gel at this time.


• Talk with your doctor before you use any other medicines or products on your skin. While you are using Retin-A Gel, you may use cosmetics.


• Do not apply Retin-A Gel to skin that is sunburned. Wait until the burn is fully healed before using Retin-A Gel.


• Do NOT use more than the recommended dose or use for longer than prescribed without checking with your doctor.


• Avoid using other topical medication, cosmetics, or other products that have a strong drying effect. If you have dry skin from using these products, allow your skin to "rest" before using Retin-A Gel.


• Do not use Retin-A Gel for any condition other than that for which it was prescribed.


• Weather extremes, such as windy or cold weather, may irritate your skin more while you are using Retin-A Gel.


• Retin-A Gel may cause harm if it is swallowed. If you may have taken it by mouth, contact your poison control center or emergency room right away.


• Retin-A Gel is flammable. Do not store or use near an open flame.


• PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Retin-A Gel while you are pregnant. If you are or will be breast-feeding while you use Retin-A Gel, check with your doctor. Discuss any possible risks to your baby.

Possible side effects of Retin-A Gel:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Redness, peeling at application site; sensitivity to sunlight; skin irritation; warmth or stinging at application site.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); severe redness, peeling, swelling, blistering, or crusting of the skin.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Retin-A side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include clumsiness; dizziness; excessive redness, peeling, and discomfort; flushing; headache; stomach pain.

Proper storage of Retin-A Gel:

Store Retin-A Gel at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store in a tightly closed container. Store away from heat and light. Do not store in the bathroom. Keep Retin-A Gel out of the reach of children and away from pets.

General information:

• If you have any questions about Retin-A Gel, please talk with your doctor, pharmacist, or other health care provider.


• Retin-A Gel is to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Retin-A Gel. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Retin-A resources

• Retin-A Side Effects (in more detail)
• Retin-A Use in Pregnancy & Breastfeeding
• Retin-A Drug Interactions
• Retin-A Support Group
• 5 Reviews for Retin-A - Add your own review/rating

Compare Retin-A with other medications

• Acne
• Lichen Sclerosus
• Necrobiosis Lipoidica Diabeticorum
• Photoaging of the Skin

Terlipressin

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

H01BA04

CAS registry number (Chemical Abstracts Service)

0014636-12-5

Chemical Formula

C52-H74-N16-O15-S2

Molecular Weight

1227

Therapeutic Categories

Vasoconstrictor

Analogue of vasopressin (antidiuretic hormone, ADH)

Chemical Names

N-[N-(N-Glycylglycyl)glycyl]-8-L-lysine vasopressin (WHO)

N-[N-(N-Glycylglycyl)glycyl]-8-L-lysinvasopressin (IUPAC)

Vasopressin, N-[N-(N-glycylglycyl)glycyl]-8-L-lysine-

Foreign Names

• Terlipressinum (Latin)
• Terlipressin (German)
• Terlipressine (French)
• Terlipresina (Spanish)

Generic Names

• Terlipressin (OS: USAN, BAN)
• Terlipressine (OS: DCF)
• TGLVP (IS)
• Triglycyllylpressin (IS)
• Glycylpressin (IS)

Brand Names

• Glypressin
  Ferring, Czech Republic; Ferring, Luxembourg; Ferring, Taiwan; Pharmaco, New Zealand



• Glypressine
  Ferring, Portugal



• Remestyp
  Ferring, Bulgaria; Ferring, Czech Republic; Ferring, Romania; Ferring, Slovakia; Ferring Leciva, Poland



• Glycylpressin
  Ferring, Germany



• Glypressin
  Ferring, Denmark; Ferring, Spain; Ferring, Greece; Ferring, Lithuania; Ferring, Malta; Ferring, Sweden; Ferring, Turkey; Ferring, Vietnam; Medinet, Estonia; Medinet, Latvia



• Haemopressin Torrex
  Torrex Chiesi, Austria



• Haemopressin
  ProReo Pharma, Switzerland; Speciality European Pharma, France



• Variquel
  Hospira Nordic, Sweden; IS Pharmaceuticals, United Kingdom



• Glipressina
  Ferring, Italy



• Glycylpressin
  Ferring, Argentina; Ferring, Austria



• Glypressin
  Ferring, United Arab Emirates; Ferring, Belgium; Ferring, Bahrain; Ferring, Switzerland; Ferring, China; Ferring, Egypt; Ferring, Finland; Ferring, United Kingdom; Ferring, Hong Kong; Ferring, Hungary; Ferring, Ireland; Ferring, Iceland; Ferring, Jordan; Ferring, Kuwait; Ferring, Lebanon; Ferring, Luxembourg; Ferring, Netherlands; Ferring, Norway; Ferring, Qatar; Ferring, Saudi Arabia; Ferring, Singapore; Ferring, Slovenia; Ferring, Syria; Ferring, Thailand; Ferring, Yemen



• Glypressine
  Ferring, France



• Haemopressin
  Meduna, Germany

International Drug Name Search

Glossary

BAN	British Approved Name
DCF	Dénomination Commune Française
IUPAC	International Union of Pure and Applied Chemistry
IS	Inofficial Synonym
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name
WHO	World Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Murelax

Murelax may be available in the countries listed below.

Ingredient matches for Murelax

Oxazepam

Oxazepam is reported as an ingredient of Murelax in the following countries:

• Australia

International Drug Name Search

Cetirizin Merck NM

Cetirizin Merck NM may be available in the countries listed below.

Ingredient matches for Cetirizin Merck NM

Cetirizine

Cetirizine dihydrochloride (a derivative of Cetirizine) is reported as an ingredient of Cetirizin Merck NM in the following countries:

• Denmark

International Drug Name Search

Proxymétacaïne

Proxymétacaïne may be available in the countries listed below.

Ingredient matches for Proxymétacaïne

Proxymetacaine

Proxymétacaïne (DCF) is also known as Proxymetacaine (Rec.INN)

International Drug Name Search

Glossary

DCF	Dénomination Commune Française
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.

Acetylcysteine Sodium

Ingredient matches for Acetylcysteine Sodium

Acetylcysteine

Acetylcysteine sodium salt (a derivative of Acetylcysteine) is reported as an ingredient of Acetylcysteine Sodium in the following countries:

• United States

International Drug Name Search

Mebeverine EG

Mebeverine EG may be available in the countries listed below.

Ingredient matches for Mebeverine EG

Mebeverine

Mebeverine hydrochloride (a derivative of Mebeverine) is reported as an ingredient of Mebeverine EG in the following countries:

• Belgium

International Drug Name Search